{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"pCR Rates and Predictors With THP in HER2-Positive Breast Cancer: EA1181\/CompassHER2 pCR","description":"What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on&amp;nbsp;her article, \u201cPathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181\/CompassHER2 pCR.\u201d&amp;nbsp;They examine differences in pCR by estrogen receptor status and the clinicopathologic and HER2DX features associated with response, while considering how these findings may inform treatment personalization as the trial\u2019s 3-year recurrence-free survival data mature. LINK TO FULL TRANSCRIPT ","author_name":"Journal of Clinical Oncology (JCO) Podcast","author_url":"http:\/\/sites.libsyn.com\/58526","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42592410\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/00457c\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/42592410"}